Rare strength powers growth – Sobi Capital Markets Day 2019

Booking.com

Swedish Orphan Biovitrum AB (publ)  (http://www.sobi.com/)(Sobi™) is hosting a Capital Markets Day at Karolinska Institutet Biomedicum in Solna, Sweden, today. Presentations from senior management and an external expert are showcasing how Sobi is well positioned to use its rare strength to expand business in Haemophilia and Immunology.

In 2018, Sobi announced both the acquisition of emapalumab from Novimmune SA and the Synagis® US franchise from AstraZeneca. These acquisitions have transformed Sobi’s business and focus, establishing a strong position in Immunology and a substantial US

Booking.com

Source: Rare strength powers growth – Sobi Capital Markets Day 2019

Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.